Luxembourg Venture Days to Unite Investors, Startups and Innovators on 16 and 17 October 2024
7.10.2024 17:57:00 EEST | Business Wire | Press release
The second edition of the Luxembourg Venture Days will gather investors, startups, and innovators in a joint summit on 16 and 17 October 2024 at Luxexpo The Box. The annual event is organised by Luxembourg’s innovation agency Luxinnovation and the Luxembourg Private Equity and VC Association (LPEA) under the umbrella of Startup Luxembourg, the country’s network to promote its startup ecosystem. This event offers a unique opportunity for investors and startups to convene, exchange, liaise and explore new strategic and investment horizons.
Luxembourg’s stands as a pivotal financial hub offering various services that attract leading investors and markets around the world. It also built a robust, stable, diversified and thriving economy and is home to around 550 startups and 15 incubators, accelerators, and innovation hubs.
The country boasts a dynamic network of business angels, with a growing number of locally managed venture capital funds.
Luxembourg’s position within a 'Greater Region' (comprising bordering territories of France Germany and Belgium) with 12 million inhabitants, its agility and accessibility, coupled with its business-friendly climate, a pragmatic approach, and an easy access to key decision-makers, makes it a hub, bridge, and springboard for investors and startups in strategic and flourishing domains such as, fintech, space, climate, health, logistics, and mobility. It attracts and invites them to participate in shaping an ecosystem with international reach that inspires innovation and fosters sustainable growth.
The growing number of European unicorns (i.e. startups valued at one billion US dollars or more) shows the progress that the European startup ecosystem has made over the past years. Matchmaking platforms and networks that connect startups and investors are key to maintain and further accelerate this momentum. Luxembourg, as an international business hub and gateway at the heart of Europe, is well positioned to stimulate the interaction between investors and entrepreneurs.
“Luxembourg is a hub, bridge, and springboard for investors and startups to explore opportunities and forge partnerships in strategic domains,” says Sasha Baillie, CEO of Luxinnovation. “The Luxembourg Venture Days will bring together several renowned and high-level events under one roof. For startups, it will be an excellent opportunity to pitch in front of a variety of investors. For investors, it will be a place to team up and find new partners and investments. We are proud to join forces with these main actors to develop our new win-win event formula and foster Luxembourg’s role as a vibrant ecosystem, home and hub for startups and investors.”
“Luxembourg is an important hub for private equity and venture capital investors as it provides an agile and accessible platform for established actors and newcomers who want to keep abreast of developments, explore new avenues, grow their investments, and create added value,” adds Stephane Pesch, CEO of LPEA.”
Registration and agenda: Luxembourg Venture Days.
The highlights of Luxembourg Venture Days 2024:
- Fit 4 Start pitching sessions (16 + 17 October)
Pitch of 60 pre-selected startups and selection 20 for the next Fit 4 Start edition - LPEA annual Insights Conference (17 October)
Full-day programme with panels and an exclusive pitching event - Keynote and masterclasses for investors and startups by US VC Jillian Manus (16 October)
- Other pitch, demo, networking, and match-making sessions (16 + 17 October)
- Tomorrow Street matchmaking breakfast with scale-ups (16 October)
- Gener8tor Demo Day (17 October)
- Luxembourg Business Angel Network (LBAN) reverse pitch (17 October)
- Luxembourg Open Innovation Club (LOIC)/ Luxinnovation Reverse Pitch (16 October)
- 8 pioneering startups to discover (17 October) – Lunch with eight Influential startups embodying our ecosystem’s potential
- Presentation of the first-ever Dealroom report on EU-backed startups (16 October)
-
Presentation of the report “Titans of Tech” 2024 by European VC GP Bullhound (16 October)
- Exclusive VC networking dinner (16 October)
- Insightful panel discussions (16 + 17 October)
- The value and benefits of investing in women-led startups (17 October)
- Navigating term sheet negotiations with investors (16 October)
- General closing ceremony (17 October) –- -Joint-programme for the large audience with:
- Keynotes by several leading profiles, including Marjut Falkstedt, CEO of the European Investment Fund
- Roundtable discussions
- Announcement of the 20 startups selected for Fit 4 Start #15; followed by a networking cocktail.
About Luxinnovation: as the national innovation agency, we empower companies to innovate today to be ready for tomorrow. We contribute to the development of the economy as a whole by identifying innovation opportunities and fostering collaborative innovation projects that stimulate the development of a sustainable, competitive and digital economy. Set up as an Economic Interest Group, Luxinnovation is supported by the Ministry of the Economy, the Ministry for Research and Higher Education, the Ministry of Foreign and European Affairs, the Luxembourg Chamber of Commerce, the Luxembourg Chamber of Skilled Crafts and FEDIL – The Voice of Luxembourg’s Industry. www.luxinnovation.lu
The Luxembourg Private Equity and Venture Capital Association (LPEA) is the most trusted and relevant representative body of private equity and venture capital practitioners with a presence in Luxembourg. Created in 2010 by a leading group of private equity and venture capital players in Luxembourg, with more than 530 members today, LPEA plays a leading role locally actively promoting PE and VC in Luxembourg. LPEA provides a dynamic and interactive platform which helps investors and advisors to navigate through latest trends in the industry. www.lpea.lu
Startup Luxembourg is the unique brand of Luxembourg's startup ecosystem, aiming at showcasing its players and innovators inside and outside the country. This is a public initiative funded by the Ministry of the Economy and managed by Luxinnovation.
www.startupluxembourg.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004816914/en/
Contacts
Jonas Mercier | Startup Luxembourg Coordinator |jonas.mercier@luxinnovation.lu |
T +352 43 62 63-858
Jean-Michel Gaudron | Head of Content Luxinnovation |
jean-michel.gaudron@luxinnovation.lu | T +352 43 62 63-684
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom